Phase 2 Non Muscle Invasive Clinical Trials
16 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–16 of 16 trials
Recruiting
Phase 1Phase 2
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Non Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC32 enrolled13 locationsNCT06637423
Recruiting
Phase 2
Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy
Non Muscle Invasive Bladder Cancer
BLATAM37 enrolled1 locationNCT06972615
Recruiting
Phase 1Phase 2
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Non Muscle Invasive Bladder Cancer
SURGE Therapeutics75 enrolled20 locationsNCT05710848
Recruiting
Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Non Muscle Invasive Bladder Cancer
Protara Therapeutics131 enrolled66 locationsNCT05951179
Recruiting
Phase 2
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
Non Muscle Invasive Bladder Cancer
White River Junction Veterans Affairs Medical Center240 enrolled9 locationsNCT05796375
Recruiting
Phase 2
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd.16 enrolled14 locationsNCT07283835
Recruiting
Phase 2
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Non Muscle Invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial Carcinoma
John Sfakianos60 enrolled4 locationsNCT06503614
Recruiting
Phase 2
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
Non Muscle Invasive Bladder Cancer
CHU de Quebec-Universite Laval160 enrolled7 locationsNCT05327647
Recruiting
Phase 1Phase 2
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Non Muscle Invasive Bladder Cancer
ImmunityBio, Inc.596 enrolled80 locationsNCT02138734
Recruiting
Phase 2
Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC
Non Muscle Invasive Bladder Cancer
Relmada Therapeutics, Inc.70 enrolled1 locationNCT06663137
Recruiting
Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Non Muscle Invasive Bladder Cancer
Robert Svatek166 enrolled2 locationsNCT04375813
Recruiting
Phase 2
Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids
Bladder CancerNon Muscle Invasive
Roland Seiler-Blarer34 enrolled1 locationNCT05024734
Recruiting
Phase 1Phase 2
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
Bladder CancerNon Muscle Invasive
Zhuhai Beihai Biotech Co., Ltd48 enrolled6 locationsNCT06732531
Recruiting
Phase 1Phase 2
OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer
Non Muscle Invasive Bladder Cancer
Binhui Biopharmaceutical Co., Ltd.30 enrolled1 locationNCT05232136
Recruiting
Phase 2
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
HER-2 Protein OverexpressionNon Muscle Invasive Bladder Cancer
Fudan University20 enrolled1 locationNCT06187506
Recruiting
Phase 2
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
HER2Non Muscle Invasive Bladder Cancer
RenJi Hospital20 enrolled1 locationNCT05957757